Pluvicto
Ended Awarded Last action
- Contract number
- 36C24826F0082
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $4,732,608
Award facts
- Contract value 100% obligated
- $4,732,607.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
Novartis Pharmaceuticals Corporation received a $4.73M firm fixed-price delivery order from Veterans Integrated Service Network 8 (VISN 8) for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical used in advanced cancer treatment. Awarded on February 24, 2026, with an ultimate completion date of August 31, 2026, this delivery order carries no small business set-aside designation. The contract will be performed at Novartis' facility in East Hanover, New Jersey, leveraging the company's established presence as a major federal supplier of oncology and nuclear medicine products to the Department of Veterans Affairs and Defense Health Agency.
This delivery order is issued under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and draws from the company's broader Blanket Purchase Agreement with VISN 10 for PLUVICTO procurement valued at $7.48M, effective through September 30, 2030. As a large pharmaceutical manufacturer without small business protections, Novartis competes directly in federal healthcare procurement and maintains multiple indefinite delivery vehicles totaling over $94M across the VA and Defense Health Agency, enabling consistent federal access to its specialized cancer therapy drugs and radiopharmaceuticals that support veteran care and military medicine missions.
Quick answers
Who was awarded contract 36C24826F0082?
36C24826F0082 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 8 (Veterans Health Administration) on February 24, 2026.
How much is contract 36C24826F0082 worth?
The government has obligated $4,732,608 on 36C24826F0082.
Is contract 36C24826F0082 an order under another contract?
Yes. 36C24826F0082 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24826F0082 competed?
The extent of competition for 36C24826F0082 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award